Evermay Wealth Management LLC Sells 376 Shares of Johnson & Johnson $JNJ

Evermay Wealth Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.9% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,029 shares of the company’s stock after selling 376 shares during the quarter. Evermay Wealth Management LLC’s holdings in Johnson & Johnson were worth $921,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. GFG Capital LLC bought a new position in shares of Johnson & Johnson during the second quarter valued at $35,000. Stone House Investment Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at $47,000. 1248 Management LLC bought a new position in shares of Johnson & Johnson during the first quarter valued at $48,000. von Borstel & Associates Inc. bought a new position in shares of Johnson & Johnson during the first quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in Johnson & Johnson during the first quarter valued at $52,000. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of research reports. Citigroup upped their price objective on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research report on Wednesday, October 15th. Sanford C. Bernstein upped their price objective on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a research report on Monday, October 6th. Wells Fargo & Company set a $212.00 price objective on Johnson & Johnson and gave the company an “overweight” rating in a research report on Friday, October 3rd. Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 8th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $200.06.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $191.93 on Wednesday. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $181.27 and a two-hundred day simple moving average of $165.37. The stock has a market cap of $462.23 billion, a price-to-earnings ratio of 18.53, a PEG ratio of 2.28 and a beta of 0.40. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be given a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.16% of the stock is currently owned by company insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.